A recent study has demonstrated that this is a viable route for C9orf72-ALS therapy, using a cell-penetrant peptide that competes with the interaction between SRSF1 and NXF1, thereby blocking nuclear export of DPR-encoding transcripts and reducing DPR production (Castelli et al., 2023). Here, SRSF1 is linked to amyotrophic lateral sclerosis.